The present multidisciplinary study examined nigrostriatal dopamine and striatal amino acid transmission in the R6/1 line of transgenic Huntington's disease (HD) mice expressing exon 1 of the HD gene with 115 CAG repeats. Although the number of tyrosine hydroxylase-positive neurons was not reduced and nigrostriatal connectivity remained intact in 16-week-old R6/1 mice, the size of tyrosine hydroxylase-positive neurons in the substantia nigra was reduced by 15%, and approximately 30% of these cells exhibited aggregated huntingtin. In addition, using in vivo microdialysis, we found that basal extracellular striatal dopamine levels were reduced by 70% in R6/1 mice compared to their wild-type littermates. Intrastriatal perfusion with malonate in R6/1 mice resulted in a short-lasting, attenuated increase in local dopamine release compared to wild-type mice. Furthermore, the size of the malonate-induced striatal lesion was 80% smaller in these animals. Taken together, these findings suggest that a functional deficit in nigrostriatal dopamine transmission may contribute to the behavioral phenotype and the resistance to malonate-induced neurotoxicity characteristic of R6/1 HD mice. 
INTRODUCTION
Huntington's disease (HD) 3 is an autosomal dominant inherited neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the HD gene coding for the protein huntingtin (Huntington's Disease Collaborative Research Group, 1993) . Huntingtin is expressed throughout the body (Sharp et al., 1995) ; however, the disease mainly affects striatal and cortical neurons (Vonsattel & DiFiglia, 1998) . The pathogenetic mechanism in HD is not known, although excitotoxicity, mitochondrial dysfunction, and dopamine (DA)-induced toxicity have been suggested to play a role (for review, see Jakel & Maragos, 2000) .
Mice transgenic for the HD gene have advanced the search for a cure. The most extensively characterized of these mice are the R6 lines which express exon 1 of the human HD gene with an expanded CAG trinucleotide repeat (115-150 CAG repeats) (Mangiarini et al., 1996) . They exhibit decreased striatal and total brain size (Mangiarini et al., 1996; Hansson et al., 1999) , dark cell degeneration (Iannicola et al., 2000; Turmaine et al., 2000) , ubiquitinated nuclear and cytoplasmic inclusion bodies (Davies et al., 1997; Li et al., 1999) , altered neurotransmitter receptor levels (Cha et al., 1998;  1 These authors contributed equally to this work. 2 To whom correspondence and reprint requests should be addressed at Section for Neuronal Survival, Wallenberg Neuroscience Center, BMC A10, S-221 84 Lund, Sweden.
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